Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE Taken together, we demonstrated that IL7 mediates an intrinsic and physiologic mechanism of GC resistance in normal thymocyte development that is retained during leukemogenesis in a subset of T-ALLs and is reversible with targeted inhibition of the IL7R/JAK/STAT5/BCL-2 axis. 31687977 2020
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE We found that T-ALL are hypersensitive to navitoclax, an inhibitor of BCL2 family of antiapoptotic proteins. 30224339 2019
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 GeneticVariation disease BEFREE These results shed new light on the oncogenic function of ribosomal mutations in cancer, provide a novel mechanism for BCL-2 upregulation in leukemia, and highlight BCL-2 inhibition as a novel therapeutic opportunity in RPL10 R98S defective T-ALL. 29930300 2019
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE Here, we evaluated the therapeutic potential of the combination of the Bcl-2 antagonist ABT-199 and cytotoxic agent gemcitabine in T-ALL cell lines. 30320607 2019
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. 30232463 2018
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. 28852199 2018
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 GeneticVariation disease BEFREE Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations. 29854301 2018
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. 28074072 2017
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE The BCL2-inhibitor venetoclax was highly active below 10 nM in B-cell precursor ALL (BCP-ALL) subsets, including <i>MLL</i><i>-AF4</i> and <i>TCF3-HLF</i> ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine. 28122742 2017
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 AlteredExpression disease BEFREE Using human T-ALL and BaF3 cell lines with high expression levels of MEF2C, the present study tested whether the BCL2 inhibitor (ABT-737) restores the sensitivity to prednisolone (PSL), because MEF2C causes PSL resistance, possibly by augmenting the anti-apoptotic activity of BCL2. 26172269 2015
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE Here we reveal that KLF4 induced apoptosis through the BCL2/BCLXL pathway in human T-ALL cell lines and primary T-ALL specimens. 25644173 2015
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE In conclusion, our study highlights BCL-2 as an attractive molecular target in specific subtypes of human T-ALL that could be exploited by ABT-199. 25301704 2014
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. 24994123 2014
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease CTD_human Here, we use RNAi technology to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression 23471820 2013
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 AlteredExpression disease BEFREE Here, we use RNAi technology to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression 23471820 2013
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE On the other hand, Fbw7-deficient T-ALL cell lines are much more resistant to the Bcl-2 antagonist, ABT-737. 21608150 2011
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 AlteredExpression disease BEFREE zeta-Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia. 20103721 2010
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE The ability of this model to detect a strong interaction between NOTCH1 and bcl2 suggests that genetic modifier screens have a high likelihood of revealing other genes that can cooperate with NOTCH1 to induce T-ALL. 17252014 2007
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 GeneticVariation disease BEFREE The p53 mutant human T acute lymphoblastic leukemia line Jurkat transduced with the Bcl-2 gene was used as model system in vitro and in a subcutaneous transplant setting in immunodeficient mice. 16916556 2006
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 AlteredExpression disease BEFREE Also, we have measured the levels of Bcl-2, Bcl-x, and Bax in 20 cases of T-ALL. 11792421 2002
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 GeneticVariation disease BEFREE Our data support the involvement of 2 distinct mechanisms: translocations involving LMO2, TAL2, and TAL1 in T cell acute lymphoblastic leukemia (T-ALL), are compatible with illegitimate V(D)J recombination between a TCR locus and a proto-oncogene locus bearing a fortuitous but functional recombination site (type 1); in contrast, translocations involving BCL1 and BCL2 in B cell non-Hodgkin's lymphomas (B-NHL), are compatible with a process in which only the IgH locus breaks are mediated by V(D)J recombination (type 2). 11781368 2002
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 AlteredExpression disease BEFREE Similar to what occurs in normal immature thymocytes, prevention of spontaneous apoptosis by IL-7 in precursor T-cell acute lymphoblastic leukemia (T-ALL) cells correlates with up-regulation of bcl-2. 11520803 2001
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE For the second criterion, in B-cell ALL, p21waf1 expression at diagnosis was the sole (albeit poorly) predictive variable, whereas bcl-2 remained of high interest in T-cell ALL. 10848789 2000
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 Biomarker disease BEFREE To further address the role of Bcl-2 in GC-mediated cytotoxicity, we generated subclones of the GC-sensitive human T-cell acute lymphoblastic leukemia line CCRF-CEM, in which transgenic Bcl-2 expression is regulated by tetracycline. 9989821 1999
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
0.400 GeneticVariation disease BEFREE We have developed and validated a quantitative polymerase chain reaction (PCR) assay targeting tumor-specific chromosomal rearrangements, including del(1) involving the tal-1 locus in pediatric T-ALL and t(14;18) involving the bcl-2 locus in follicular lymphoma. 10233841 1999